News stories about Fibrocell Science (NASDAQ:FCSC) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fibrocell Science earned a news impact score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.200912617709 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several analysts recently issued reports on the stock. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reissued a “buy” rating and issued a $7.60 price target on shares of Fibrocell Science in a research report on Thursday, October 5th. Canaccord Genuity reissued a “buy” rating and issued a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. Finally, ValuEngine downgraded shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $5.21.
Fibrocell Science (NASDAQ FCSC) traded down $0.08 during midday trading on Tuesday, hitting $1.29. The stock had a trading volume of 208,700 shares, compared to its average volume of 91,909. Fibrocell Science has a 12 month low of $1.26 and a 12 month high of $4.64.
ILLEGAL ACTIVITY WARNING: “Fibrocell Science (FCSC) Receives News Sentiment Rating of 0.10” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2017/12/05/fibrocell-science-fcsc-receives-news-sentiment-rating-of-0-10.html.
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
What are top analysts saying about Fibrocell Science Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fibrocell Science Inc and related companies.